Professor Paul Workman OBE has been awarded the Enrst W. Bertner Memorial Award by The University of Texas MD Anderson Cancer Center, for his distinguished contributions to cancer research. The award, ...

New research has found that a rare form of triple-negative breast cancer has a generally favourable long-term prognosis and may not require the same treatment approach as more common triple-negative ...

PENELOPE B is a phase III international, multicentre, randomised, placebo-controlled, double-blind trial comparing the efficacy and safety of adding palbociclib to standard hormone therapy vs standard ...

What is the study about? STAR-TRAP investigates treatment options for prostate cancer which has grown in small areas around the body (metastatic prostate cancer). People with metastatic prostate ...

Christine O’Connell set up the One More City fundraising campaign after she was diagnosed with breast cancer. She and her cycling teammates have raised more than £500,000 to support much-needed ...

Merenienla Yaden is a Research Administrator at the Institute of Cancer Research, contributing to the NHS Jewish BRCA Testing Programme within Professor Clare Turnbull’s team in the Division of ...

What is the study about? HER2-RADiCAL is investigating whether some people with HER2 positive breast cancer can safely receive less treatment after surgery. HER2 is a protein which can cause cancer to ...

Research Data Manager: Integrative Cancer Epidemiology Email: [email protected] Location: Sutton Email: [email protected] Location: Sutton Home Research and discoveries Find a researcher ...

Advocacy engagement: policy and public affairs Our policy priorities Creating a sustainable funding model for research in universities Encouraging international talent to support cancer research ...

Twenty years ago today, the International Genome Sequencing Consortium published the first detailed analysis of the human genome. The paper appeared online in Nature on 15 February 2001, followed by a ...

The National Institute for Health and Care Excellence (NICE) criteria used to decide who should be referred by GPs for further breast cancer risk assessment and specialist care misses up to 95 per ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...